Diagnostic difficulties and treatment progress of primary gastric lymphoma

doi:10.16352/j.issn.1001-6325.2023.09.1462

Abstract

Abstract: Primary gastric lymphoma (PGL) is the most common gastric malignant tumor except gastric cancer, most of which have no specific clinical symptoms. It is usually not accurately diagnosed. And it is prone to misdiagnosis and missed diagnosis. The main treatments include surgery, radiotherapy, chemotherapy and targeted therapy. And the immunotherapy is expected to be a potential treatment modality. Understanding the difficulties in the diagnosis process is the guarantee of accurate diagnosis and the basis for subsequent precision treatment.

Key words: primary gastric lymphoma, misdiagnosis, immunotherapy, immune checkpoint inhibitor

CLC Number:

R735.2

DAI Di, LIU Yuqin. Diagnostic difficulties and treatment progress of primary gastric lymphoma[J]. Basic & Clinical Medicine, 2023, 43(9): 1462-1466.

References 26

[1]	吕远, 王晓娜, 梁寒. 原发性胃淋巴瘤200例临床分析[J]. 中华胃肠外科杂志, 2012, 15: 157-160.
[2]	Carboni F, Diodoro MG, Valle M. Synchronous primary diffuse large B cell lymphoma and adenocarcinoma of the stomach: a clinical dilemma[J]. Indian J Surg Oncol, 2020, 11: 223-225.
[3]	Meguro M, Someya T, Ohmura T, et al. Collision cancer of primary squamous cell carcinoma and adenocarcinoma in the stomach after treatment for a non-Hodgkin′s lymphoma of diffuse large B cell type:a case report[J]. Nihon Shokakibyo Gakkai Zasshi, 2020, 117: 334-344.
[4]	Fukunaga H, Asama H, Kaneda H, et al. Collision tumor with diffuse large B cell lymphoma and gastric cancer[J]. Jpn J Clin Oncol, 2016, 46: 968-969.
[5]	Kilaru S, Panda SS, Das H, et al. Primary gastric Hodgkin′s lymphoma: a rare coincidence[J]. Cancer Treat Res Commun, 2020, 24: 100194.doi:10.1016/j.ctarc.2020.100194.
[6]	Zhang L, Zhang P, Wen J, et al. Primary gastric natural killer/T-cell lymphoma with diffuse CD30 expression and without CD56 expression: a case report[J]. Oncol Lett, 2016, 11: 969-972.
[7]	Saber MM. Diagnostic performance of PD-L1 versus PD-1 expression in circulating CD20 cells in diffuse Large B-cell lymphoma[J]. Antibodies (Basel), 2022, 11.doi: 10.3390/antib11010015.
[8]	Chen Y, Li M, Cao J, et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression[J]. Open Life Sci, 2021, 16: 909-919.
[9]	American association for cancer research.LAG3-PD-1 Combo impresses in melanoma[J]. Cancer Discov, 2021, 11: 1605-1606.
[10]	Jiang X, Zhang H, Ni J, et al. Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development[J]. Front Oncol, 2022, 12: 1060496.doi: 10.3389/fonc.2022.1060496.
[11]	Nagasaki J, Togashi Y, Sugawara T, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-Ⅱ-expressing tumors such as classic Hodgkin lymphoma[J]. Blood Adv, 2020, 4: 4069-4082.
[12]	Ma J, Pang X, Li J, et al. The immune checkpoint expression in the tumor immune microenvironment of DLBCL: clinicopathologic features and prognosis[J]. Front Oncol, 2022, 12: 1069378.doi: 10.3389/fonc.2022.1069378.
[13]	Morrissey MA, Williamson AP, Steinbach AM, et al. Chimeric antigen receptors that trigger phagocytosis[J]. Elife, 2018, 7.doi: 10.7554/eLife.36688.
[14]	Dovedi SJ, Elder MJ, Yang C, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells[J]. Cancer Discov, 2021, 11: 1100-1117.
[15]	Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers[J]. ESMO Open, 2022, 7: 100336. doi: 10.1016/j.esmoop.2021.100336.
[16]	Shi Y, Su H, Song Y, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab[J]. EBioMedicine, 2020, 54: 102731.doi: 10.1016/j.ebiom.2020.102731.
[17]	Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors[J]. Nat Med, 2020, 26: 688-692.
[18]	Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396: 839-852.
[19]	Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380: 45-56.
[20]	Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma[J]. Blood, 2021, 137: 2634-2645.
[21]	Albinger N, Pfeifer R, Nitsche M, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia[J]. Blood Cancer J, 2022, 12: 61.doi: 10.1038/s41408-022-00660-2.
[22]	Soldierer M, Bister A, Haist C, et al. Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies[J]. Front Immunol, 2022, 13: 847008. doi: 10.3389/fimmu.2022.847008.
[23]	Mukhopadhyay M. Macrophages enter CAR immunotherapy[J]. Nat Methods, 2020, 17: 561.doi: 10.1038/s41592-020-0862-4.
[24]	Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy[J]. Nat Biotechnol, 2020, 38: 947-953.
[25]	Zhang W, Liu L, Su H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix[J]. Br J Cancer, 2019, 121: 837-845.
[26]	Kang M, Lee SH, Kwon M, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy[J]. Adv Mater, 2021, 33: e2103258.doi: 10.1002/adma.202103258.